Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Syngene InternationalBOM:539268 +0.86%81 PB Ratio is 3.35 as of Aug. 09, 2026, which is 53% below its 10-year median of 7.06. GuruFocus rates BOM:539268 with a GF Score™ of 81/100 and a GF Value™ of ₹727.53 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, Syngene International ranks worse than 68.04% on this metric.
Syngene International Ltd stock PB Ratio (=3.35) is close to 10-year low of 3.25.
The historical rank and industry rank for Syngene International's PB Ratio or its related term are showing as below:
BOM:539268'
s PB Ratio Range Over the Past 10 Years
Min: 3.25 Med: 7.06 Max: 10.59
Current: 3.35
During the past 13 years, Syngene International's highest PB Ratio was 10.59. The lowest was 3.25. And the median was 7.06.
BOM:539268's PB Ratio is ranked worse than 68.04% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.195
vs BOM:539268: 3.35
During the past 12 months, Syngene International's average Book Value Per Share Growth Rate was 2.30% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 10.00% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 11.80% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 16.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Syngene International was 44.00% per year. The lowest was 10.00% per year. And the median was 21.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Syngene International's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Syngene International PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Syngene International's PB Ratio distribution charts can be found below:
* The bar in red indicates where Syngene International's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Syngene International (BOM:539268) has a PB Ratio of 3.35 as of Aug. 09, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Syngene International and its competitors. This is 53% below median its historical median of 7.06. Over the past decade, Syngene International's PB Ratio has ranged from 3.25 to 10.59. According to the industry distribution chart, Syngene International ranks #132 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 68%.
Is Syngene International's PB Ratio too high?
Syngene International's current PB Ratio of 3.35 is 53% below median its 10-year median of 7.06. Over the past 10 years, this metric has ranged from a low of 3.25 to a high of 10.59. The Medical Diagnostics & Research industry median PB Ratio is 2.20. Syngene International's value of 3.35 is 52.6% above this industry median. Based on the distribution chart, Syngene International ranks #132 out of 194 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Syngene International has a GF Score™ of 81/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Syngene International's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Syngene International ranks #132 out of 194 companies for PB Ratio. This places Syngene International in the lower half of its industry. The industry median PB Ratio is 2.20. Syngene International's value of 3.35 is 52.6% above this benchmark. Historically, Syngene International's own PB Ratio has ranged from 3.25 to 10.59 over the past decade. While the company's 10-year median is 7.06 vs. the industry median of 2.20, Syngene International has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.20, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Syngene International's current PB Ratio of 3.35 is 52.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Syngene International and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Syngene International's current PB Ratio is 3.35, which is 53% below median its own 10-year median of 7.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Syngene International stock overvalued right now?
Based on GuruFocus' analysis, Syngene International (BOM:539268) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹727.53, compared to a current price of ₹403.45 — trading 44.5% below its estimated fair value. The current PB Ratio is 3.35, which is 53% below median its 10-year median of 7.06 and 52.6% above the Medical Diagnostics & Research industry median of 2.20. Syngene International's overall GF Score™ is 81/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Syngene International (BOM:539268), the current PB Ratio is 3.35 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Syngene International (BOM:539268) Overvalued in 2026?
Based on GuruFocus' analysis, Syngene International stock appears to be undervalued.
The current stock price of ₹403.45 is trading 44.5% below its estimated GF Value™ of ₹727.53.
GuruFocus considers Syngene International to be Significantly Undervalued.
Key valuation signals for BOM:539268:
PB Ratio: 3.35 (53% below median its 10-year median of 7.06)
GF Value™: ₹727.53 vs. price of ₹403.45 (44.5% below fair value)
Industry Position: 52.6% above the Medical Diagnostics & Research median (#132 of 194)
No single metric tells the full story. See the BOM:539268 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Syngene International Ltd is a contract research and manufacturing organization in India. It supports research and development programs, from lead generation to clinical and commercial supplies. The Company is engaged in a single operating segment of providing contract research and manufacturing services. The company operates in India, the United States of America and other countries, of which a majority of the revenue is derived from the USA. The company receives revenue by providing contract research and manufacturing services. It offers services such as Oligonucleotide synthesis, Bioinformatics, Clinical development services, polymer research, chemical development, safety assessment, discovery chemistry, discovery biology, and others.
81GF Score
Get the complete analysis for BOM:539268
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:539268 has been successfully added to your 
